SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · APH

AMPHENOL REPORTS RECORD THIRD QUARTER 2026 RESULTS

Amphenol Corp. · Filed · SEC Form 8-K, Item 2.02

Amphenol Corp. company page Original on SEC.gov ↗

Revenue $10.2 billion +65% vs a year ago
EPS $0.79 +61% vs a year ago
Guidance revisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue rose 65% year on year to $10.2 billion, and EPS grew 61% to $0.79. Growth in both sales and earnings is the combination investors usually look for first. The company revised its guidance; the original release shows which items moved and by how much.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$10.2 billion +65% vs a year ago

…Sales of $10.2 billion, up 65% in U.S. dollars and 37% organically compared to the third quarter of 2025…
EPS

$0.79 +61% vs a year ago

…GAAP Diluted EPS of $0.79, up 61% compared to prior year…
Guidance

Guidance revised

…to generate full-year sales of $5.1 billion and to be $0.18 accretive to the Company’s Adjusted Diluted EPS in 2026 which is reflected in our outlook.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.